Pfiz­er’s lat­est copy­cat could put the squeeze on Roche — again

Pfiz­er $PFE is bar­rel­ing for­ward on its plans to recre­ate Roche’s stal­wart can­cer drugs, an­nounc­ing pos­i­tive da­ta this morn­ing for its Rit­ux­an copy­cat called PF …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER